ICU Medical, Inc. $ICUI Shares Acquired by Sei Investments Co.

Sei Investments Co. lifted its holdings in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 40.8% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 48,632 shares of the medical instruments supplier’s stock after acquiring an additional 14,093 shares during the period. Sei Investments Co.’s holdings in ICU Medical were worth $6,281,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of ICUI. Millennium Management LLC raised its position in shares of ICU Medical by 173.4% in the 3rd quarter. Millennium Management LLC now owns 1,089,017 shares of the medical instruments supplier’s stock valued at $130,638,000 after purchasing an additional 690,694 shares during the last quarter. Norges Bank purchased a new stake in ICU Medical during the 4th quarter worth approximately $58,083,000. Thrivent Financial for Lutherans grew its position in ICU Medical by 1,604.0% during the 4th quarter. Thrivent Financial for Lutherans now owns 303,457 shares of the medical instruments supplier’s stock worth $43,294,000 after purchasing an additional 285,648 shares during the last quarter. UBS Group AG increased its stake in ICU Medical by 239.8% during the 3rd quarter. UBS Group AG now owns 386,555 shares of the medical instruments supplier’s stock valued at $46,371,000 after purchasing an additional 272,782 shares in the last quarter. Finally, Brown Advisory Inc. acquired a new position in ICU Medical during the 4th quarter valued at approximately $32,445,000. Institutional investors and hedge funds own 96.10% of the company’s stock.

ICU Medical Stock Up 2.6%

ICUI stock opened at $172.94 on Tuesday. The firm’s fifty day simple moving average is $148.81 and its 200-day simple moving average is $140.40. The company has a market capitalization of $4.32 billion, a P/E ratio of 93.48, a price-to-earnings-growth ratio of 2.35 and a beta of 0.76. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.34 and a quick ratio of 1.17. ICU Medical, Inc. has a 12 month low of $107.00 and a 12 month high of $176.27.

ICU Medical (NASDAQ:ICUI) last issued its earnings results on Thursday, May 7th. The medical instruments supplier reported $1.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.78 by $0.19. The firm had revenue of $525.77 million during the quarter, compared to analysts’ expectations of $520.65 million. ICU Medical had a net margin of 2.15% and a return on equity of 7.50%. The firm’s revenue was down 12.3% compared to the same quarter last year. During the same quarter last year, the company posted $1.72 earnings per share. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. As a group, equities research analysts forecast that ICU Medical, Inc. will post 6.51 earnings per share for the current year.

Insider Activity

In other news, VP Virginia Ruth Sanzone sold 2,447 shares of the company’s stock in a transaction dated Thursday, May 14th. The stock was sold at an average price of $124.08, for a total value of $303,623.76. Following the sale, the vice president owned 19,460 shares in the company, valued at $2,414,596.80. This represents a 11.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David C. Greenberg sold 2,424 shares of the company’s stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $122.91, for a total value of $297,933.84. Following the completion of the sale, the director owned 7,960 shares in the company, valued at $978,363.60. The trade was a 23.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 2.10% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Sanford C. Bernstein downgraded shares of ICU Medical to a “market perform” rating in a research note on Monday, June 15th. BTIG Research started coverage on ICU Medical in a research report on Monday, June 15th. They issued a “buy” rating and a $170.00 target price on the stock. Zacks Research lowered ICU Medical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Needham & Company LLC raised ICU Medical from a “hold” rating to a “buy” rating and set a $165.00 price target for the company in a research report on Wednesday, May 27th. Finally, Piper Sandler dropped their price target on ICU Medical from $178.00 to $163.00 and set an “overweight” rating on the stock in a research note on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, ICU Medical currently has an average rating of “Moderate Buy” and a consensus price target of $172.00.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.